Login to Your Account



Financings Roundup

ActoGeniX Series B to Move IBD Program to IND Stage

By Marie Powers
Staff Writer

Friday, April 19, 2013
ActoGeniX NV closed a Series B equity financing round, raising €10.7 million (US$14 million) to move its ActoBiotics program to the investigational new drug application (IND) stage in a second indication of inflammatory bowel disease (IBD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription